Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease

Annals of Allergy Asthma & Immunology(2022)10.1016/j.anai.2022.01.043Source: DataRank Database

Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease is a research paper published in Annals of Allergy Asthma & Immunology (2022). On theSindex it has a DataRank of 0. It has been cited 36 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access36 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 5.09)OA: greenTopics (19)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Camille M. Steger,Deborah Gakpo,Jillian C. Bensko ORCID,Rie Maurer ORCID,Tanya M. Laidlaw ORCID

Live enrichment

PubMed:35131410 PMC:PMC9058196 OpenAlex:https://openalex.org/W4210267731

NIAID NIH HHS

Grant: T32 AI007306

NIAID NIH HHS

Grant: K23 AI139352

NHLBI NIH HHS

Grant: R01 HL128241

NIAID NIH HHS

Grant: U19 AI095219

National Institutes of Health

Regeneron Pharmaceuticals Inc

FWCI

5.09

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: https://www.elsevier.com/legal/tdmrep-license

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9058196

publisherhttps://api.elsevier.com/content/article/PII:S1081120622000904?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1081120622000904?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.anai.2022.01.043

Fields of Study

Drug-Induced Adverse ReactionsInflammatory mediators and NSAID effectsInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

MeSH Terms

AspirinBiological ProductsDesensitization, ImmunologicFemaleHumansSinusitisAsthma, Aspirin-InducedPatient Outcome Assessment

Keywords

MedicineDupilumabDesensitization (medicine)AspirinOdds ratioAdverse effectInternal medicineAsthma

Sustainable Development Goals

SDG 0: Good health and well-being

Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease

FAIR Checklist

Authors (7)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)